Literature DB >> 18724393

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

B E Shaw1, G J Mufti, S Mackinnon, J D Cavenagh, R M Pearce, K E Towlson, J F Apperley, R Chakraverty, C F Craddock, M A Kazmi, T J Littlewood, D W Milligan, A Pagliuca, K J Thomson, D I Marks, N H Russell.   

Abstract

Disease relapse following an allogeneic transplant remains a major cause of treatment failure, often with a poor outcome. Second allogeneic transplant procedures have been associated with high TRM, especially with myeloablative conditioning. We hypothesized that the use of reduced-intensity conditioning (RIC) would decrease the TRM. We performed a retrospective national multicentre analysis of 71 patients receiving a second allogeneic transplant using RIC after disease relapse following an initial allogeneic transplant. The majority of patients had leukaemia/myelodysplasia (MDS) (N=57), nine had lymphoproliferative disorders, two had myeloma and three had myeloproliferative diseases. A total of 25% of patients had unrelated donors. The median follow-up was 906 days from the second allograft. The predicted overall survival (OS) and TRM at 2 years were 28 and 27%, respectively. TRM was significantly lower in those who relapsed late (>11 months) following the first transplant (2 years: 17 vs 38% in early relapses; P=0.03). Two factors were significantly associated with a better survival: late relapse (P=0.014) and chronic GVHD following the second transplant (P=0.014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant.

Entities:  

Mesh:

Year:  2008        PMID: 18724393     DOI: 10.1038/bmt.2008.255

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  25 in total

1.  When is second allogeneic HSCT for relapse of acute leukaemia an option?

Authors:  M Christopeit
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

2.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

Authors:  Marcos de Lima; David L Porter; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Christoph Schmid
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Hematopoietic stem cell transplantation for MDS.

Authors:  Matthias Bartenstein; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.

Authors:  Ann Dahlberg; Wendy Leisenring; Marie Bleakley; Soheil Meshinchi; K Scott Baker; Corinne Summers; Brandon Hadland; Colleen Delaney; Kanwaldeep Mallhi; Lauri Burroughs; Paul Carpenter; Ann Woolfrey
Journal:  Bone Marrow Transplant       Date:  2019-01-22       Impact factor: 5.483

5.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

6.  Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.

Authors:  I Bilmon; I Nivison-Smith; M Hertzberg; D Ritchie; M Greenwood; A Spencer; G Kennedy; A Bryant; J Moore
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

7.  Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

Authors:  Christine N Duncan; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Jean-Yves Cahn; Haydar A Frangoul; Robert J Hayashi; Jack W Hsu; Rammurti T Kamble; Kimberly A Kasow; Nandita Khera; Hillard M Lazarus; Alison W Loren; David I Marks; Richard T Maziarz; Paulette Mehta; Kasiani C Myers; Maxim Norkin; Joseph A Pidala; David L Porter; Vijay Reddy; Wael Saber; Bipin N Savani; Harry C Schouten; Amir Steinberg; Donna A Wall; Anne B Warwick; William A Wood; Lolie C Yu; David A Jacobsohn; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-12       Impact factor: 5.742

8.  Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Authors:  Philip H Imus; Amanda L Blackford; Maria Bettinotti; Brian Iglehart; August Dietrich; Noah Tucker; Heather Symons; Kenneth R Cooke; Leo Luznik; Ephraim J Fuchs; Robert A Brodsky; William H Matsui; Carol Ann Huff; Douglas Gladstone; Richard F Ambinder; Ivan M Borrello; Lode J Swinnen; Richard J Jones; Javier Bolaños-Meade
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-25       Impact factor: 5.742

9.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

Review 10.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.

Authors:  Jeffrey C Bryan; Elias J Jabbour
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.